Delving into the Latest Updates on Mianserin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [2]

Target

NET x α-adrenergic receptor

Mechanism

NET agonists(Norepinephrine transporter agonists), α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Depressive Disorder

Inactive Indication-

Originator Organization

Merck & Co., Inc.

Active Organization

Organon KK

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Mar 2001),

Depressive Disorder

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H21ClN2

InChIKeyYNPFMWCWRVTGKJ-UHFFFAOYSA-N

CAS Registry21535-47-7

Patients with depression with sleep problems have functional abnormalities of 5-HT and NE neurotransmitters, and the NaSSA class antidepressant mianserin has an ameliorative effect on sleep problems along with antidepressant. However, whether mianserin can improve cognitive function in patients still needs to be explored. The benzodiazepine lorazepam can play a central inhibitory role and has good therapeutic effect on insomnia. The mechanism of action of mianserin and lorazepam is different, and there are few comparative studies related to the combination of the two with SSRI drugs for the treatment of depressed patients with sleep problems, and it is unclear whether there are differences in their efficacy and safety. Therefore, to address the above scientific questions, this study was designed to include 100 patients aged 18-60 years with depression with sleep problems, randomly divided into two groups and treated with mianserin + escitalopram or lorazepam + escitalopram, respectively, and followed up for 8 weeks to assess depression and anxiety symptoms, sleep, cognitive function and drug safety. To compare the efficacy and safety of the two regimens in depressed patients with sleep problems and to provide a scientific basis for clinical intervention in depressed patients with sleep problems.

Start Date01 Jul 2024

Sponsor / Collaborator

Shanghai Mental Health Center

[+1]

JPRN-UMIN000026579 / CompletedIIT

Pharmacokinetics of mianserin suppository in Japanese elderly healthy volunteers -a pilot study - Pharmacokinetics of mianserin suppository in healthy volunteers

Start Date17 Feb 2017

Sponsor / Collaborator-

NCT02761161 / CompletedPhase 4IIT

Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial

The overall aim of this study is to examine the effects of sleep enhancing treatment in refugees with PTSD.

Start Date01 Mar 2016

Sponsor / Collaborator-

100 Clinical Results associated with Mianserin Hydrochloride

Login to view more data

100 Translational Medicine associated with Mianserin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Mianserin Hydrochloride

Login to view more data

1,988

Literatures (Medical) associated with Mianserin Hydrochloride

01 Oct 2024·Neuropsychopharmacology

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants

Article

Author: Støve, Svein I ; Ramsey, Amy J ; Salahpour, Ali ; Miller, Gary W ; Finnie, Peter S B ; Lipina, Tatiana V ; Bucher, Meghan L ; Marmouzi, Ilias ; Williams, Erin Q ; Yan, Yuanye ; Wang, Xunan

AbstractVesicular monoamine transporter 2 (VMAT2) is an essential transporter that regulates brain monoamine transmission and is important for mood, cognition, motor activity, and stress regulation. However, VMAT2 remains underexplored as a pharmacological target. In this study, we report that tricyclic and tetracyclic antidepressants acutely inhibit, but persistently upregulate VMAT2 activity by promoting VMAT2 protein maturation. Importantly, the VMAT2 upregulation effect was greater in BE(2)-M17 cells that endogenously express VMAT2 as compared to a heterologous expression system (HEK293). The net sustained effect of tricyclics and tetracyclics is an upregulation of VMAT2 activity, despite their acute inhibitory effect. Furthermore, imipramine and mianserin, two representative compounds, also demonstrated rescue of nine VMAT2 variants that cause Brain Monoamine Vesicular Transport Disease (BMVTD). VMAT2 upregulation could be beneficial for disorders associated with reduced monoamine transmission, including mood disorders and BMVTD, a rare but often fatal condition caused by a lack of functional VMAT2. Our findings provide the first evidence that small molecules can upregulate VMAT2 and have potential therapeutic benefit for various neuropsychiatric conditions.

01 Jun 2024·Neuropsychopharmacology Reports

Vortioxetine‐induced syndrome of inappropriate secretion of antidiuretic hormone: A case report

Article

Author: Shindo, Yunosuke ; Yasui-Furukori, Norio ; Kikuchi, Kota ; Sasaki, Taro ; Kawamata, Yasushi ; Sugawara, Norio

AbstractBackgroundVortioxetine, known for its efficacy in treating depression through its effects on various neurotransmitters, has not been previously reported to induce syndrome of inappropriate secretion of antidiuretic hormone (SIADH).Case PresentationThis case report describes a 74‐year‐old man with major depressive disorder who developed SIADH 1 week after starting treatment with vortioxetine. SIADH is characterized by symptoms such as headache, nausea, disorientation, and seizures, stemming from hyponatremia (123 mEq/L), without dehydration or edema. Vortioxetine was discontinued, and an alternative drug, mianserin, was initiated. The patient was restricted from drinking water due to hyponatremia. The serum Na concentration improved over time to within the normal range by the second week after admission.ConclusionThis is the first case report of vortioxetine‐induced SIADH.

01 May 2024·Acta Psychiatrica Scandinavica

Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial

Article

Author: Andersen, Frederik Mølkjær ; Ziersen, Simon Christoffer ; Kessing, Lars Vedel ; Gerds, Thomas ; Budtz-Jørgensen, Esben

AbstractBackgroundLong‐term studies comparing nonresponse to antidepressants for major depressive disorder (MDD) are lacking.AimsTo present systematic population‐based nation‐wide register data on comparative 2‐year non‐response within six antidepressant drug classes and 17 different antidepressants in patients with MDD.MethodThe study included all 106,920 patients in Denmark with a first main index diagnosis of MDD at a psychiatric hospital inpatient or outpatient contact and who subsequently had a purchase of an antidepressant in the period from 1995 to 2018. Non‐response to first antidepressant within a 2‐year study period was defined as switch to or add‐on of another antidepressant, antipsychotic medication, lithium, or hospitalization. Analyses emulated a targeted trial in populations standardized according to age, sex, socioeconomic status, and comorbidity with psychiatric and physical disorders.ResultsCompared with sertraline, there was no difference for citalopram (RR: 1.00 [95% CI: 0.98–1.02]) but fluoxetine (1.13 [95% CI: 1.10–1.17]), paroxetine (1.06 [95% CI: 1.01–1.10]) and escitalopram (1.22 [95% CI: 1.18–1.25]) were associated with higher risk ratio of non‐responses. Within selective noradrenaline reuptake inhibitors, sertraline outperformed reboxetine; within serotonin‐norepinephrine reuptake inhibitors, venlafaxine outperformed duloxetine; within noradrenergic and specific serotonergic antidepressants, mirtazapine outperformed mianserin and within the class of other antidepressants, sertraline outperformed agomelatine and vortioxetine. Within tricyclic antidepressants, compared to amitriptyline, nortriptyline, dosulepin, and clomipramine had higher non‐response, whereas there was no difference for imipramine.ConclusionsThese analyses emulating a randomized trial of “real world” observational register‐based data show that 2‐year long‐term non‐responses to some antidepressants within six different drug classes are increased over others.

100 Deals associated with Mianserin Hydrochloride

Login to view more data